MENARINI is a fully integrated privately owned pharma company with a long and successful heritage in strategic partnering across the globe. We have a profound know-how stemming from our strong R&D capabilities in key therapeutic areas, coupled with our excellence in commercial execution and our powerful direct presence on a global basis.
Allergic rhinitis
Allergic rhinitis (AR) is a symptomatic disorder of the nose induced after allergen exposure due to an IgE-mediated inflammation of the membranes lining the nose. It is characterized by nasal symptoms including anterior or posterior rhinorrhea, sneezing, nasal blockage and/or itching of the nose and it is often accompanied by ocular symptoms (redness, itching, burning, watery eyes). Furthermore, AR is a common comorbidity of asthma that contributes to its development and severity.
AR is subdivided into "intermittent" or "persistent" disease; the severity of the disease can be classified as "mild" or "moderate/severe". The burden of AR is often under-estimated since the disease is not life-threatening; however, it adversely affects many aspects of daily life such as the quality of sleep, school/work performances, daily life.